American Journal of Cardiology
Volume 101, Issue 8, Supplement , Pages S44-S47 , 17 April 2008

Niacin and Lipoprotein(a): Facts, Uncertainties, and Clinical Considerations

  • Angelo M. Scanu, MD

      Affiliations

    • Department of Medicine, University of Chicago, Chicago, Illinois, USA
    • Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois, USA.
    • Corresponding Author InformationAddress for reprints: Angelo M. Scanu, MD, University of Chicago, Department of Medicine, MC 5041, 5841 South Maryland Avenue, Chicago, Illinois 60637.
    • ,
  • Ravi Bamba, BS

      Affiliations

    • Department of Medicine, University of Chicago, Chicago, Illinois, USA

References 

  1. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol. 2007;18:415–442
  2. Sanyal S, Karas RH, Kuvin JT. Present-day uses of niacin: effects on lipid and non-lipid parameters. Expert Opin Pharmacother. 2007;8:1711–1718
  3. Aetschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem. 1955;54:558–559
  4. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–381
  5. Knopp RH. Evaluating niacin in its various forms. Am J Cardiol. 2000;86(suppl):51L–56L
  6. Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease. J Nutr Biochem. 2003;14:298–305
  7. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug (A 50th anniversary review). J Intern Med. 2005;258:94–114
  8. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271–276
  9. Maher VMG, Brown BG, Marcovina S, Hillger LA, Zhao X-Q, Albers J. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995;274:1771–1774
  10. Morgan JM, Capuzzi D, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998;82(suppl):29U–34U
  11. Capuzzi D, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long term study. Am J Cardiol. 1998;82:74U–81U
  12. McKenney JM, Jones P, Bays H, Knopp R, Kashyap M, Ruoff G, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL [Comparative Effects on Lipid Levels of Niaspan and Statins Versus Other Lipid Therapies] study). Atherosclerosis. 2007;192:432–437
  13. Pan J, Van JT, Chan E, Kesala RL, Lin M, Charles MA. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. Metabolism. 2002;51:1120–1127
  14. Pan J, Lin M, Kesala RL, Van J, Charles MA. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes Metab. 2002;4:255–261
  15. Scanu AM. Lp(a) lipoprotein—coping with heterogeneity. N Engl J Med. 2003;349:2089–2090
  16. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem. 2003;49:1785–1796
  17. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199–204
  18. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol. 1999;10:225–236
  19. Edelstein C, Davidson NO, Scanu AM. Oleate stimulates the formation of the triglyceride-rich particles containing apoB100-apo(a) in long term primary cultures of human hepatocytes. Chem Phys Lipids. 1994;67:135–14368
  20. Bonen DK, Hausman AML, Hadjiagapiou C, Skarosi SF, Davidson NO. Expression of a recombinant apolipoprotein(a) in HepG2 cells. J Biol Chem. 1997;272:5659–5667
  21. Nassir F, Bonen DK, Davidson NO. Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion. J Biol Chem. 1998;273:17793–17800
  22. Edelstein C, Pfaffinger D, Hinamn J, Miller E, Lipkind G, Tsimikas S, et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem. 2003;278:52841–52847
  23. Klezovitch O, Edelstein C, Scanu AM. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a): evidence for a critical involvement of elements of its C-terminal domain. J Biol Chem. 2001;276:46864–46869
  24. Tsimikas S, Brilakis ES, Miller ER, McConell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46–57
  25. Atac IA, Peksel A, Yanardag R, Sokmen BB, Doger MM, Bilen ZG. The effect of combined treatment with niacin and chromium (III) chloride on the different tissues of hyperlipemic rats. Drug Chem Toxicol. 2006;29:363–377
  26. Kuvin JT, Dave DM, Sliney AS, Mooney P, Patel AR, Kimmelstiel CD, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary heart disease. Am J Cardiol. 2006;98:743–745

 This work was supported by grant HL-63209 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland.Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)00255-5

doi: 10.1016/j.amjcard.2008.02.031

American Journal of Cardiology
Volume 101, Issue 8, Supplement , Pages S44-S47 , 17 April 2008

Article Tools

* Image Usage & Resolution